References
- 1. HÉNIQUE C, PAPISTA C, GUYONNET L, LENOIR O, THARAUX P-L. Update on crescentic glomerulonephritis. Semin Immunopathol. 2014;36(4):479-490.
- 2. MORONI G, PONTICELLI C. Rapidly progressive crescentic glomerulonephritis: early treatment is a must. Autoimmun Rev. 2014; 13(7): 723-729.
- 3. BONSIB S-M. Glomerular basement membrane necrosis and crescent organization. Kidney Int. 1988; 33(5): 966-974.
- 4. QUIROGA B, VEGA A, RIVERA F, LOPEZ-GOMEY J. Crescentic glomerulonephritis: data from the Spanish Glomerulonephritis Registry. Intern Med J. 2015; 45(5): 557-562.
- 5. BALDWIN DS, NEUGARTEN J, FEINER H-D, GLUCK M, SPINOWITZ B. The existence of a protracted course in crescentic glomerulonephritis. Kidney Int. 1987; 31(3): 790-794.
- 6. JENNETTE J-C. Rapidly progressive crescentic glomerulonephritis. Kidney Int. 2003; 63(3): 1164-1177.
- 7. TARZI R-M, COOK H-T, PUSEY C-D. Crescentic glomerulonephritis: new aspects of pathogenesis. Semin Nephrol. 2011;31(4): 361-368.
- 8. ATKINS R-C, NIKOLIC-PATERSON D-J, SONG Q, LAN H-Y. Modulators of crescentic glomerulonephritis. J Am Soc Nephrol. 1996; 7(11): 2271-2278.
- 9. CATTRAN DC, FEEHALLY J, COOK HT, LIU ZH, FERVENZA FC, MEZZANO SA. et al. Kidney disease: improving global outcomes (KDIGO) glomerulonephritis work group. KDIGO clinical practice guideline for glomerulonephritis. Kidney Int Supp.2012; 2(2): 139-274.
- 10. ROBSON J, DOLL H, SUPPIAH R, FLOSSMANN O, HARPER L, HÖGLUND P. et al. Damage in the ANCA-associated vasculitides: long-term data from the European vasculitis study group (EUVAS) therapeutic trials. Ann Rheum Dis. 2015; 74(1): 177-184.
- 11. OZTURK R, YENIGUN EC, DEDE F, KOC E, TURGUT D, PISKINPASA S-V. et al. Prognostic factors in crescentic glomerulonephritis: a single-center experience. Iran J Kidney Dis. 2015; 9(1):31-38.
- 12. HEILMAN R-L, OFFORD K-P, HOLLEY K-E, VELOSA J-A. Analysis of risk factors for patient and renal survival in crescentic glomerulonephritis. Am J Kidney Dis. 1987; 9(2): 98-107.
- 13. BERDEN A-E, FERRARIO F, HAGEN E-C, JAYNE D-R, JENNETTE J-C, JOH K. et al. Histopathologic classification of ANCA-associated glomerulonephritis. J Am Soc Nephrol. 2010; 21(10): 1628-1636.
- 14. LEVY J-B, TURNER A-N, REES A-J, PUSEY C-D. Long-term outcome of anti-glomerular basement membrane antibody disease treated with plasma exchange and immunosuppression. Ann Intern Med. 2001; 134(11): 1033-1042.
- 15. WEIDNER S, GEUSS S, HAFEZI-RACHTI S, WONKA A, RUPPRECHT H-D. ANCA-associated vasculitis with renal involvement: an outcome analysis. Nephrol Dial Transpl. 2004; 19(6): 1403-1411.
- 16. SONSINO E, NABARRA B, KAZATCHKINE M, HINGLAIS N, KREIS H. Extracapillary proliferative glomerulonephritis so-called malignant glomerulonephritis. Adv Nephrol Necker Hosp. 1972; 2: 121.
- 17. WHITWORTH J-A, MOREL-MAROGER L, MIGNON F, RICHET G. The significance of extracapillary proliferation. Nephron. 1976; 16(1): 1-19.
- 18. CHOUDHURY T-A, SINGH R-G, SINGH S, SINGH T-B, RATHORE S-S. Clinicopathologic spectrum of crescentic glomerulonephritis: A hospital-based study. Saudi J Kidney Dis Transpl. 2014; 25(3): 689.
- 19. COUSER W-G. Rapidly progressive glomerulonephritis: classification, pathogenetic mechanisms, and therapy. Am J Kidney Dis. 1988; 11(6): 449-464.